Kyongbo Pharmaceutical Co., Ltd (214390.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	279.6B	264.1B	238.6B	216.4B	196.3B
Cost of Revenue	175.4B	166.3B	156.1B	153.3B	151.8B
Gross Profit	104.1B	97.8B	82.4B	63.1B	44.4B
Operating Expenses
R&D Expense	14.8B	19.6B	5.3B	3.7B	3.1B
SG&A Expense	46.7B	58.8B	47.0B	35.8B	24.0B
General & Admin Expense	3.7B	4.8B	2.4B	2.4B	1.9B
Selling & Marketing Expense	28.2B	54.0B	44.7B	33.4B	22.1B
Other Expenses	60.5B	15.9B	19.6B	18.1B	15.9B
Total Operating Expenses	101.5B	94.3B	72.0B	57.5B	43.0B
Cost and Expenses	276.9B	260.6B	228.1B	210.8B	194.9B
Operating Income (EBIT)	2.6B	3.5B	10.5B	5.5B	1.4B
Non-Operating
Interest Income	6.3B	41.3M	70.3M	143.4M	14.4M
Interest Expense	6.3B	4.3B	4.3B	3.4B	1.7B
Net Interest Income	78.1M	(4.2B)	(4.2B)	(3.3B)	(1.7B)
Other Non-Op Income/Expense	3.3B	(3.1B)	(5.6B)	(3.4B)	(2.0B)
Non-Operating Income (excl Interest)	—	—	1.3B	(28.1M)	336.4M
EBT (Pre-Tax Income)	6.0B	449.5M	4.9B	2.2B	(614.8M)
Income Tax Expense	1.0B	267.2M	263.7M	(802.5M)	(1.2B)
Bottom Line
Net Income	5.0B	182.3M	4.6B	3.0B	610.6M
Earnings from Cont. Ops	5.0B	182.3M	4.6B	3.0B	610.6M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	5.0B	182.3M	4.6B	3.0B	610.6M
Per Share
Basic EPS	₩208	₩8	₩194	₩124	₩26
Diluted EPS	₩208	₩8	₩194	₩124	₩26
Revenue Per Share	₩11,693	₩11,063	₩9,979	₩9,050	₩8,210
Shares
Basic Shares Outstanding	23.9M	23.9M	23.9M	23.9M	23.9M
Diluted Shares Outstanding	23.9M	23.9M	23.9M	23.9M	23.9M
Profitability Metrics
EBITDA	16.7B	16.7B	21.6B	17.2B	12.8B
D&A	14.1B	13.2B	12.4B	11.7B	11.7B
EBIT	2.6B	3.5B	9.2B	5.6B	1.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026